EUVIMEDEUVIMED entdecken
Open Access

Inhalable Stem Cell Exosomes Promote Heart Repair After Myocardial Infarction

Junlang Li iD, Shenghuan Sun iD, Dashuai Zhu iD, Xuan Mei iD, Yongbo Lyu, Ke Huang iD, Yuan Li iD, Shuo Liu iD, Zhenzhen Wang iD, Shiqi Hu iD, Halle J Lutz iD, Kristen D Popowski iD und 3 weitere

Circulation · 27.08.2024 · 150 (9) · 710-723

DOI: 10.1161/circulationaha.123.065005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 27.08.2024. Verfasst von Junlang Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University (J.L., Y.L., Y.L., Z.W.). Hauptthemen laut MEDLINE: Myocardial Infarction, Exosomes, Mice, Inbred C57BL. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Exosome therapy shows potential for cardiac repair after injury. However, intrinsic challenges such as short half-life and lack of clear targets hinder the clinical feasibility. Here, we report a noninvasive and repeatable method for exosome delivery through inhalation after myocardial infarction (MI), which we called stem cell–derived exosome nebulization therapy (SCENT). METHODS: Stem cell–derived exosomes were characterized for size distribution and surface markers. C57BL/6 mice with MI model received exosome inhalation treatment through a nebulizer for 7 consecutive days. Echocardiographies were performed to monitor cardiac function after SCENT, and histological analysis helped with the investigation of myocardial repair. Single-cell RNA sequencing of the whole heart was performed to explore the mechanism of action by SCENT. Last, the feasibility, efficacy, and general safety of SCENT were demonstrated in a swine model of MI, facilitated by 3-dimensional cardiac magnetic resonance imaging. RESULTS: Recruitment of exosomes to the ischemic heart after SCENT was detected by ex vivo IVIS imaging and fluorescence microscopy. In a mouse model of MI, SCENT ameliorated cardiac repair by improving left ventricular function, reducing fibrotic tissue, and promoting cardiomyocyte proliferation. Mechanistic studies using single-cell RNA sequencing of mouse heart after SCENT revealed a downregulation of Cd36 in endothelial cells (ECs). In an EC- Cd36 fl/− conditional knockout mouse model, the inhibition of CD36, a fatty acid transporter in ECs, led to a compensatory increase in glucose utilization in the heart and higher ATP generation, which enhanced cardiac contractility. In pigs, cardiac magnetic resonance imaging showed an enhanced ejection fraction (Δ=11.66±5.12%) and fractional shortening (Δ=5.72±2.29%) at day 28 after MI by SCENT treatment compared with controls, along with reduced infarct size and thickened ventricular wall. CONCLUSIONS: In both rodent and swine models, our data proved the feasibility, efficacy, and general safety of SCENT treatment against acute MI injury, laying the groundwork for clinical investigation. Moreover, the EC- Cd36 fl/− mouse model provides the first in vivo evidence showing that conditional EC-CD36 knockout can ameliorate cardiac injury. Our study introduces a noninvasive treatment option for heart disease and identifies new potential therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial InfarctionExosomesMice, Inbred C57BLAnimalsMiceAdministration, InhalationDisease Models, AnimalSwineMyocytes, CardiacMaleVentricular Function, LeftHumansMyocardiumStem CellsCD36 Antigens

Stichwörter der Autor:innen

CD36exosomesextracellular vesiclesinhalationmyocardial infarction

Substanzen

CD36 Antigens

Autor:innen und Institutionen

  • Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University (J.L., Y.L., Y.L., Z.W.).
  • Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh (J.L., Y.L., K.H., Y.L., Z.W., H.J.L., K.D.P., P.-U.C.D.).
  • Xsome Biotech Inc, Raleigh, NC (J.L.).
  • Bakar Computational Health Sciences Institute, University of California, San Francisco (S.S., A.J.B.).
  • Department of Biomedical Engineering (D.Z., S.L., S.H., K.C.), Columbia University, New York, NY.
  • Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA (X.M.).

ORCID-Profile: Junlang Li, Shenghuan Sun, Dashuai Zhu, Xuan Mei, Ke Huang, Yuan Li, Shuo Liu, Zhenzhen Wang, Shiqi Hu, Halle J Lutz, Kristen D Popowski, Phuong-Uyen C Dinh, Atul J Butte, Ke Cheng

Förderung

  • NHLBI NIH HHS
  • NIH HHS

Zitieren

APA

Li, J., Sun, S., Zhu, D., Mei, X., Lyu, Y., Huang, K., Li, Y., Liu, S., Wang, Z., Hu, S., Lutz, H. J., Popowski, K. D., Dinh, P. C., Butte, A. J., & Cheng, K. (2024). Inhalable Stem Cell Exosomes Promote Heart Repair After Myocardial Infarction. Circulation, 150(9), 710-723. https://doi.org/10.1161/circulationaha.123.065005

Vancouver

Li J, Sun S, Zhu D, Mei X, Lyu Y, Huang K, et al. Inhalable Stem Cell Exosomes Promote Heart Repair After Myocardial Infarction. Circulation. 2024;150(9):710-723. doi:10.1161/circulationaha.123.065005

BibTeX
@article{Li2024,
  author = {Li, Junlang and Sun, Shenghuan and Zhu, Dashuai and Mei, Xuan and Lyu, Yongbo and Huang, Ke and Li, Yuan and Liu, Shuo and Wang, Zhenzhen and Hu, Shiqi and Lutz, Halle J and Popowski, Kristen D and Dinh, Phuong-Uyen C and Butte, Atul J and Cheng, Ke},
  title = {Inhalable Stem Cell Exosomes Promote Heart Repair After Myocardial Infarction},
  journal = {Circulation},
  year = {2024},
  volume = {150},
  number = {9},
  pages = {710--723},
  doi = {10.1161/circulationaha.123.065005}
}
Kostenlos starten →